

Supplemental Table 5. Morphological outcomes of infant monkeys exposed to vedolizumab *in utero*.

Parameter,	Group 1		Group 2		Group 3	
mean (SD),	Vedolizumab		Vedolizumab		Vedolizumab	
cm ^a	0 mg/kg/day Q2W		10 mg/kg/day Q2W		100 mg/kg/day Q2W	
	PPD 1	PPD 181 ^b	PPD 1	PPD 181 ^b	PPD 1	PPD 181 ^b
	N=7	N=7	N=7	N=7	N=10	N=10
Distance between eyes	1.7 (0.1)	2.1 (0.1)	1.8 (0.2)	2.3 (0.1)	1.8 (0.1)	2.3 (0.1)
Crown-rump length	16.0 (1.3)	25.3 (0.9)	17.1 (0.7)	25.4 (1.3)	17.2 (0.6)	27.0 (2.1)
Crown-heel length	25.2 (1.5)	39.1 (2.2)	25.3 (1.1)	40.1 (2.0)	25.9 (1.1)	40.9 (1.8)
Tail length	19.9 (2.1)	26.5 (2.4)	21.1 (2.2)	28.9 (2.8)	20.6 (1.6)	29.3 (4.3)
Chest circumference	12.8 (0.5)	19.1 (1.0)	13.1 (0.5)	18.9 (1.2)	12.9 (0.7)	19.3 (0.9)
Rt arm length	8.4 (0.9)	14.6 (1.4)	8.1 (1.0)	15.7 (1.0)	8.5 (0.9)	15.4 (1.3)
Lt arm length	8.0 (1.5)	14.3 (1.4)	8.1 (1.1)	15.0 (1.2)	8.4 (1.1)	15.3 (1.1)
Rt leg length	6.3 (0.8)	11.4 (0.9)	6.3 (0.6)	12.2 (3.1)	6.7 (0.7)	11.6 (1.0)
Lt leg length	6.2 (0.9)	11.2 (1.0)	6.2 (0.7)	11.9 (3.3)	6.5 (0.6)	11.6 (1.0)
Ano-genital distance, males ^c	3.6 (-)	6.3 (-)	3.5 (0.7)	6.2 (0.9)	3.3 (1.0)	5.9 (0.9)

Ano-genital

distance, 1.9 (0.2) 3.2 (0.6) 1.5 (-) 2.7 (-) 1.7 (0.4) 3.0 (0.7)

females^d

Lt, left; PPD, postpartum day; Rt, right; Q2W, every 2 weeks.

^a Some measurements included only 6 infants in Group 1 and only 9 infants in Group 3.

^b PPD 181 ± 1 day.

^c There were 2 males in Group 1, and 5 each in Groups 2 and 3.

^d There were 5 females in Group 1, 2 females in Group 2, and 5 females in group 3.